JP2019536429A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536429A5 JP2019536429A5 JP2019514037A JP2019514037A JP2019536429A5 JP 2019536429 A5 JP2019536429 A5 JP 2019536429A5 JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019514037 A JP2019514037 A JP 2019514037A JP 2019536429 A5 JP2019536429 A5 JP 2019536429A5
- Authority
- JP
- Japan
- Prior art keywords
- epitopes
- virus
- polyomavirus
- subject
- infection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims description 125
- 241001505332 Polyomavirus sp. Species 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 54
- 108090000623 proteins and genes Proteins 0.000 claims description 54
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 51
- 241000701460 JC polyomavirus Species 0.000 claims description 43
- 206010028980 Neoplasm Diseases 0.000 claims description 36
- 201000011510 cancer Diseases 0.000 claims description 34
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 28
- 108091008874 T cell receptors Proteins 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 24
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 18
- 208000001676 Polyomavirus Infections Diseases 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- 241000700605 Viruses Species 0.000 claims description 12
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 241000701022 Cytomegalovirus Species 0.000 claims description 10
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 210000000716 merkel cell Anatomy 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 5
- 230000028993 immune response Effects 0.000 claims description 4
- 238000009169 immunotherapy Methods 0.000 claims description 4
- 206010055181 BK virus infection Diseases 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000000338 in vitro Methods 0.000 claims description 3
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 2
- 102000015789 HLA-DP Antigens Human genes 0.000 claims description 2
- 108010010378 HLA-DP Antigens Proteins 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000002955 isolation Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000000644 propagated effect Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 9
- 230000009258 tissue cross reactivity Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023000505A JP7821133B2 (ja) | 2016-09-09 | 2023-01-05 | ポリオーマウイルスのための免疫療法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662385456P | 2016-09-09 | 2016-09-09 | |
| US62/385,456 | 2016-09-09 | ||
| PCT/US2017/050686 WO2018049165A1 (en) | 2016-09-09 | 2017-09-08 | Immunotherapy for polyomaviruses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000505A Division JP7821133B2 (ja) | 2016-09-09 | 2023-01-05 | ポリオーマウイルスのための免疫療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536429A JP2019536429A (ja) | 2019-12-19 |
| JP2019536429A5 true JP2019536429A5 (https=) | 2020-10-22 |
Family
ID=61562223
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514037A Pending JP2019536429A (ja) | 2016-09-09 | 2017-09-08 | ポリオーマウイルスのための免疫療法 |
| JP2023000505A Active JP7821133B2 (ja) | 2016-09-09 | 2023-01-05 | ポリオーマウイルスのための免疫療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023000505A Active JP7821133B2 (ja) | 2016-09-09 | 2023-01-05 | ポリオーマウイルスのための免疫療法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200197439A1 (https=) |
| EP (1) | EP3509632A4 (https=) |
| JP (2) | JP2019536429A (https=) |
| KR (2) | KR20240133760A (https=) |
| CN (1) | CN109922830A (https=) |
| AU (2) | AU2017322397A1 (https=) |
| BR (1) | BR112019004102A2 (https=) |
| CA (1) | CA3035906A1 (https=) |
| IL (1) | IL265103B2 (https=) |
| MX (1) | MX2019002566A (https=) |
| PH (1) | PH12019500344A1 (https=) |
| RU (1) | RU2019110269A (https=) |
| SG (1) | SG11201901166QA (https=) |
| WO (1) | WO2018049165A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3000183T3 (en) | 2018-09-10 | 2025-02-27 | Atara Biotherapeutics Inc | Methods for expanding antigen-specific car-t cells, compositions and uses related thereto |
| CA3148391A1 (en) * | 2019-07-24 | 2021-01-28 | The Council Of The Queensland Institute Of Medical Research | Immunotherapy for polyomaviruses |
| CN113278634B (zh) * | 2020-11-16 | 2022-06-28 | 艾棣维欣(苏州)生物制药有限公司 | 一种预防和治疗默克尔细胞癌的新型疫苗 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2361930A3 (en) * | 2007-03-26 | 2011-10-26 | Dako Denmark A/S | Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases |
| CN105505870B (zh) * | 2016-01-20 | 2017-07-25 | 深圳市中美康士生物科技有限公司 | 免疫细胞培养方法以及人工滋养细胞在免疫细胞培养中的用途 |
-
2017
- 2017-09-08 KR KR1020247027913A patent/KR20240133760A/ko active Pending
- 2017-09-08 CA CA3035906A patent/CA3035906A1/en active Pending
- 2017-09-08 BR BR112019004102-8A patent/BR112019004102A2/pt active Search and Examination
- 2017-09-08 AU AU2017322397A patent/AU2017322397A1/en not_active Abandoned
- 2017-09-08 KR KR1020197009875A patent/KR102698554B1/ko active Active
- 2017-09-08 JP JP2019514037A patent/JP2019536429A/ja active Pending
- 2017-09-08 RU RU2019110269A patent/RU2019110269A/ru unknown
- 2017-09-08 MX MX2019002566A patent/MX2019002566A/es unknown
- 2017-09-08 IL IL265103A patent/IL265103B2/en unknown
- 2017-09-08 US US16/331,414 patent/US20200197439A1/en not_active Abandoned
- 2017-09-08 CN CN201780067349.9A patent/CN109922830A/zh active Pending
- 2017-09-08 EP EP17849612.1A patent/EP3509632A4/en active Pending
- 2017-09-08 WO PCT/US2017/050686 patent/WO2018049165A1/en not_active Ceased
- 2017-09-08 SG SG11201901166QA patent/SG11201901166QA/en unknown
-
2019
- 2019-02-18 PH PH12019500344A patent/PH12019500344A1/en unknown
-
2023
- 2023-01-05 JP JP2023000505A patent/JP7821133B2/ja active Active
-
2024
- 2024-11-15 AU AU2024264673A patent/AU2024264673A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6995645B2 (ja) | 免疫原性ｗｔ１ペプチド及びその使用方法 | |
| RU2721574C2 (ru) | Вакцинная композиция против злокачественной опухоли | |
| US9919037B2 (en) | Immunogenic WT-1 peptides and methods of use thereof | |
| JP4185147B2 (ja) | Ｋｄｒペプチド及びこれを含むワクチン | |
| JP7364237B2 (ja) | 癌治療のためのｔ細胞の活性化方法 | |
| US9265816B2 (en) | Immunogenic WT-1 peptides and methods of use thereof | |
| CN106029699B (zh) | Wt1抗原性多肽和含有该多肽的抗肿瘤剂 | |
| US20240368220A1 (en) | Immunogenic wt-1 peptides and methods of use thereof | |
| BR112020004221A2 (pt) | célula dendrítica pró-inflamatória, composição farmacêutica, e, método para prover células dendríticas pró-inflamatórias | |
| JP2025003964A (ja) | 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 | |
| JP2019536429A5 (https=) | ||
| JP2025106402A (ja) | がん治療のためのｔ細胞の活性化方法 | |
| CN101643497A (zh) | Lmp2a蛋白来源的hla-a2限制性表位多肽及其用途 | |
| JP7844327B2 (ja) | ポリオーマウイルスのための免疫療法 | |
| JP6871432B2 (ja) | Ｐｌｋ１タンパク質に対する抗原に特異的なｔ細胞の免疫反応を誘導するｈｌａ−ａ２亜型に特異的なｐｌｋ１由来の抗原決定基 | |
| Reimann et al. | Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains | |
| CN109535231B (zh) | 人T细胞病毒抗原蛋白Tax的CTL特异性识别表位及其应用 | |
| Cervantes-Torres et al. | Understanding the Anti-Tumor Properties Mediated by | |
| US10722563B2 (en) | Prostate-specific tumor antigens and uses thereof | |
| Melief | Peptide-based therapeutic cancer vaccines | |
| CN104761636A (zh) | 一种HLA-A33限制性eEF2表位多肽及其应用 | |
| Ke | Study of NY-ESO-1 Specific Cytotoxic T Lymphocytes ex vivo | |
| Conesa et al. | Su. 32. Expression of Natural Cytotoxic Receptors by NK Cells from HCV-infected Patients | |
| HK1229830B (zh) | Wt1抗原性多肽和含有该多肽的抗肿瘤剂 |